Iron Overload : A Cause of Primary Amenorrhea

Maj Nikita Naredi*, Lt Col Atul Seth⁺, Col Ajay Sharma[#]

MJAFI 2011; 67 : 86-87

Key Words : Primary amenorrhea; Thalassemia major; Iron overload

Introduction

Primary amenorrhea i.e. absence of menses, resulting from hypogonadotropic hypogonadism occurs when the hypothalamus fails to secrete adequate amounts of gonadotropin releasing hormone (GnRH) or when a pituitary disorder is associated with inadequate production or release of pituitary gonadotropins [1]. Thalassemia major, a severe hemolytic anaemia due to a genetic defect in the synthesis of haemoglobin chain, can produce hypopituitarism. This hypopituitarism leads to hypogonadotropic hypogonadism, an endocrinopathy occurring secondary to iron overload [2]. The iron overload is a consequence of frequent blood transfusion, which is the most important treatment modality for thalassemia major. Other possible causes of hypogonadism in beta thalassemia major include liver disorders, chronic hypoxia, diabetes mellitus and zinc deficiency [3]. The anterior pituitary is especially sensitive to increased iron concentration which disrupts the hormonal secretion leading to hypogonadism, short stature and acquired hypothyroidism [4].

We present a case of primary amenorrhea in a thalassemic patient to highlight that hypertransfusion and regular chelation therapy may have allowed improved survival in patients with thalassemia major but despite medical advances, growth failure and hypogonadism remains a significant clinical problem in these patients in adolescence.

Case Report

A 19 year old unmarried girl, a known case of thalassemia major reported to the gynaecological outpatient department OPD with primary amenorrhea and poor development of secondary sexual characters. She gave history of receiving monthly blood transfusions since she was nine months of age and daily injections of desferrioxamine as a chelating

agent. She gave no history of weight loss, night sweats, headaches, or visual disturbances.

On examination, she was a thinly built, short statured girl with a height of 145 cm. She had a hypoplastic nose with a thalassemic facies. The girl had mild pallor, but no thyromegaly, acanthosis nigricans, or galactorrhea. Her breast development was prepubertal (Tanner Stage I) and pubic hair growth was Tanner stage II. The abdominal examination was within normal limits with no organomegaly. Gynaecological examination revealed the external genitalia to be prepubertal. Per speculum and vaginal examination was not carried out due to her unmarried status. However, uterus could be felt on per rectal examination.

Laboratory investigations including whole hematological and biochemical parameters were carried out which were essentially normal except haemoglobin of 7.5 gm/dL and serum ferritin of 6072.24 ng/ml (N: 50-150 ng/ml). A detailed endocrinological profile was also conducted which was suggestive of hypogonadotropic hypogonadism (Table 1).

Ultrasonography of the pelvis revealed a small uterus with small sized right ovary and non visualization of the left ovary. magnetic resonance imaging (MRI) of the pelvis showed small uterus (13mm x 19mm x 40 mm) and hypo plastic ovaries. MRI of the brain was suggestive of pituitary iron overload with a small sella and a reduced size of the pituitary gland. The clinical and endocrinological profile confirmed hypogonadotropic hypogonadism. Based on this diagnosis the patient was started on hormone replacement therapy to mature and maintain her secondary sexual characteristics. She was put on conjugated estrogens and cyclical progestins to prevent unopposed estrogen stimulation of the

Table 1

Hormonal assay of the patient

Hormones assayed	Patient values	Reference values
FSH	0.01 IU/L	1.30-1.50 IU/L
LH	0.44 IU/L	0.5-27.0 IU/L
Estradiol	17 pg/ml	20-400 pg/ml
TSH	5.97 mIU/ml	5.5-6.5 mIU/ml

*Graded Specialist (Obstetrics & Gynaecology), [#]Senior Advisor (Medicine & Haematology), AH (R&R), New Delhi-10. ⁺Classified Specialist (Obstetrics & Gynaecology), Command Hospital (SC), Pune-40.

endometrium. Patient is on regular follow up and compliant with her treatment.

Discussion

The thalassemias are a heterogeneous group of genetic disorders in which the production of one or more globin chains of hemoglobin is suppressed. Depending on the defective chain, several types of thalassemias have been described like α and β thalassemia. Frequent transfusion and chelation therapy is the most important treatment modality which has considerably prolonged the survival of thalassemic patients [5]. However, as a result of hypertransfusion therapy and prolonged longevity, iron tissue toxicity has become more common and contributes significantly to many structural, metabolic and endocrine consequences in these patients like hypothyroidism, hypogonadism and diabetes mellitus [6].

Hypogonadism resulting from iron induced pituitary dysfunction is the most frequently reported endocrine abnormality in patients with β thalassemia major [7]. Hypogonadism is clinically diagnosed in a female by the presence of primary or secondary amenorrhea with absent or poor development of secondary sexual characteristics. The history and clinical findings are substantiated by the laboratory investigations which was present in this patient. The circulating gonadotropins are inappropriately low and the levels of estradiol are extremely below the normal values. The anterior pituitary which is sensitive in a dose dependant manner to the effects of iron overload can be imaged by MRI. It may show empty sella, decreased pituitary size or thinning of the stalk as was demonstrated in this girl [8].

Serum ferritin levels indicates the efficacy of chelation therapy and was disproportionately higher (6072.24ng/ml) in the present case. Multiple endocrinopathies, including hypogonadism, hypothyroidism and diabetes mellitus has been observed in patients who tend to have high serum ferritin levels [9]. Hypothyroidism and diabetes mellitus was however not present in our patient. The mainstay of treatment of hypogonadism consists of hormone replacement therapy with sex steroids. Sex steroids are important for the maintenance of normal body composition, skeletal health

and induction and maturation of secondary sexual characteristics. It is the most important form of replacement therapy in patients not desirous of fertility [10]. Our patient being a young unmarried girl has been started on estrogens and cyclical progestin therapy.

Timely recognition and prevention of the endocrine complications, by early and regular chelation therapy is mandatory for the improvement of the quality of life and favourable psychological outcome of thalassemic patients.

Conflicts of Interest

None identified

References

- Schillings WJ, McClamrock HD. Amenorrhea. In: Berek & Novak's Gynecology. 14th Ed USA: Lippincott Williams & Wilkins 2007; 1035-65.
- Karamifar H, Karimi M, Amirhakimi GH, Badieli M. Endocrine functions in Thalassemia Intermedia. International Journal of Bioedical Science 2006; 2: 236-40.
- De Sanctis V. Growth and puberty and its management in Thalassemia. Horm Res 2002; 58: 72-9.
- Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with Thalassemia Major. Paediatric Endocrinol Rev 2007; 5: 642-8.
- Agrawal MB. Advances in the management of Thalassemia. Indian Pediatrics 2004; 41: 989-92.
- Lukens JN. The thalassemia and related disorders. In: Jonathan W, Pine Jr, Editor. Wintrobe, Clinical Hematology. 10th ed. USA: Williams and Wilkins 1999; 1405-49.
- Christfordis A, Haritandi A, Perifanis V, Tsatra I, Metaxa M, Dimitradis AS. MRI for the determination of pituitary iron overload in children and young adults with beta-thalassemia major. Eur J Radiol 2007; 62: 138-42.
- Soliman AT, Eizaalabeny MM, Ragab M. Spontaneous and GnRH provoked Gonadotropin secretion and testosterone response to Human Chorionic Gonadotropin in adolescent boys with thalassemia major and delayed puberty. J Trop Pediatr 2000; 46: 79-85.
- Low LC. Growth, puberty and endocrine function in beta thalassemia major. J Paediatr Endocrinol Metab 1997; 10: 175-84.
- Pallais JC, Caudill M, Pitteloud N, Seminara S, Crowley Jr WF. Hypogonadotropic Hypogonadism Overview. In: Pagon RA, Bird TC, Dolan CR, Stephens K, editors. Gene Reviews. Seattle (WA): University of Washington, Seattle 1993.